TuHURA Biosciences (NASDAQ:HURA) (NASDAQ: HURA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, dedicated to accelerating the discovery and development of novel small molecule therapeutics. Founded in 2014 as a spin-out of Seal Rock Partners, TuHURA’s name is derived from the Māori word for “to discover,” reflecting its commitment to unveiling new targets and modalities through advanced scientific methodologies. The company combines the latest in artificial intelligence, computational biology and structural proteomics to streamline every stage of the drug discovery process, from target identification to lead optimization.
At the core of TuHURA’s approach is its proprietary integrated platform, which fuses deep learning algorithms with high-throughput phenotypic screening, crystallography and chemoproteomics. This unified strategy allows TuHURA scientists to rapidly deconvolute complex biological pathways, predict off-target effects and design chemical probes with high specificity. The company’s pipeline spans multiple therapeutic areas, with a particular focus on oncology, immuno-oncology and fibrosis. Early-stage programs target novel intracellular proteins and epigenetic regulators that have historically proven difficult to drug.
In addition to its in-house discovery efforts, TuHURA has established collaborations with leading pharmaceutical and academic institutions to expand its reach and validate its platform in diverse disease settings. The company maintains R&D laboratories in Cambridge and partners with contract research organizations across North America and Europe. These alliances support joint research projects, co-development arrangements and enable access to specialized assays and translational models.
Leadership at TuHURA draws on decades of expertise in biotech innovation, medicinal chemistry and computational science. Under the guidance of its Chief Executive Officer, Dr. Scott Hall, and Chief Scientific Officer, Dr. Jane Thompson, the company has built a multidisciplinary team of chemists, biologists and data scientists. Together, they aim to deliver first-in-class drug candidates with the potential to address unmet medical needs and generate durable patient benefit.
